Former Pfizer staffers counter pharma giant’s ‘belated and ill-founded’ trade secrets casenews2022-03-23T13:50:37+00:00March 23rd, 2022|FierceBiotech|
Pfizer’s $7B bet delivers phase 3 success, advancing bid to establish new drug in ulcerative colitis Arenanews2022-03-23T12:30:16+00:00March 23rd, 2022|FierceBiotech|
Despite 0% response rate, 4D hits primary endpoint in Keytruda combo trial, sending stock skywardnews2022-03-23T11:08:14+00:00March 23rd, 2022|FierceBiotech|
LifeMine locks down $70M ‘dream scenario’ fungi partnership with GSK—and a fundraising, toonews2022-03-22T18:27:52+00:00March 22nd, 2022|FierceBiotech|
NIH-backed HDT Bio sues Indian partner for $950M, alleging it stole trade secretsnews2022-03-22T17:28:18+00:00March 22nd, 2022|FierceBiotech|
Ocelot Bio gets a cool $36M series A and a new CEO to bootnews2022-03-22T15:29:37+00:00March 22nd, 2022|FierceBiotech|
ORIC walks away from lead cancer resistance program after lackluster phase 1b datanews2022-03-22T13:58:28+00:00March 22nd, 2022|FierceBiotech|
Aligos hacks off 2nd hep B med since January after ‘unexpected’ reaction in 4 patientsnews2022-03-22T13:57:05+00:00March 22nd, 2022|FierceBiotech|
Moderna trains its mRNA tech on the common cold and a triple whammy against 3 respiratory diseasesnews2022-03-22T13:04:15+00:00March 22nd, 2022|FierceBiotech|
After going 0 for 2, AnaptysBio CEO makes immediate exit, leaving a strategic portfolio review in his wakenews2022-03-22T11:40:32+00:00March 22nd, 2022|FierceBiotech|
